Fig. 5From: Dabigatran etexilate for thromboprophylaxis in over 5000 hip or knee replacement patients in a real-world clinical settingCumulative incidence of sVTE or all-cause mortality over time from the start of treatment, treated set. No new events occurred after day 33 in THR patients or day 27 in TKR patients. sVTE symptomatic venous thromboembolism, THR total hip replacement, TKR total knee replacementBack to article page